Research progress of immune-related pneumonia caused by PD-1/PD-L1 inhibitor
10.3760/cma.j.cn371439-20200609-00091
- VernacularTitle:PD-1/PD-L1抑制剂引起免疫相关性肺炎的研究进展
- Author:
Bo SONG
1
;
Mingxin WU
;
Yingjie JIA
;
Xiaojiang LI
Author Information
1. 天津中医药大学第一附属医院肿瘤科 300381
- From:
Journal of International Oncology
2020;47(10):627-629
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of immune-related pneumonia caused by programmed death-1/programmed death ligand-1 inhibitors is low, but the risk is high. Patients with non-small cell lung cancer who have pre-existing lung diseases or have received chest radiotherapy are more likely to develop pneumonia, but their clinical symptoms are not typical, which reduces the survival benefit of patients. Delaying immunotherapy early and rationally using glucocorticoids and immunosuppressants can relieve clinical symptoms and improve prognosis.
